Details for Patent: 10,786,444
✉ Email this page to a colleague
Which drugs does patent 10,786,444 protect, and when does it expire?
Patent 10,786,444 protects VAZALORE and is included in one NDA.
This patent has twenty patent family members in nine countries.
Summary for Patent: 10,786,444
| Title: | PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same |
| Abstract: | Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia. |
| Inventor(s): | Upendra Marathi, Susann Childress, Shaun Gammill, Robert W. Strozier |
| Assignee: | Plx Acquisition Company LLC |
| Application Number: | US16/833,371 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,786,444
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-002 | Feb 26, 2021 | OTC | Yes | No | ⤷ Start Trial | ⤷ Start Trial | A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY | ⤷ Start Trial | ||||
| Plx Pharma | VAZALORE | aspirin | CAPSULE;ORAL | 203697-001 | Jan 14, 2013 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,786,444
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012315545 | ⤷ Start Trial | |||
| Canada | 2850187 | ⤷ Start Trial | |||
| China | 103957888 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
